Pre-Conference Workshop Day
Tuesday February 25, 2025

Pre-Conference Workshop Day

Tuesday 25th February 2025

8:30am Registration & Morning Coffee

9:00am Workshop A

Advancing Tech Transfer for Hybrid Modalities to Meet Deadlines & Deliver Drugs Faster

Synopsis

Pinpointing continuous failures and troubleshooting can be time consuming and result in downtime. This workshop will ensure you are equipped with the technical knowledge to perfect your small-scale operations and futureproof scale-up to shorten time to market. Delve into tech transfer case-studies for small molecule and small-scale advancements for large biologics to understand how to maintain end-to-end product consistency:

  • Advancing your process understanding to help facilitate tech transfer
  • Discussing analytical advancements and techniques to better understand early-stage analytics
  • Understanding opportunities for digitalization to better understand your processes

Breakout Session

Join your peers’ post-presentations to discuss over a series of questions applicable to your area of specialty

No day selected
No day selected

11:00am Morning Refreshment Break

11:30am Workshop B

Training to Think in Continuous: Adopting Continuous Manufacturing Cross-Learnings Between Modalities to Translate Across the Complete Pipeline

  • Yuxin He Senior Engineer II (PAT), Moderna
  • Terrence Dobrowsky Head of Biotherapeutics Technology Development & Implementation, Takeda

Synopsis

  • Developing an internal mindset to embrace continuous processing to enhance cost-efficient production along the pipeline
  • Considering best internal practices to reprioritize continuous manufacturing and build a strong business case for efficient manufacturing alternatives
  • Understanding small molecule applications to be applied to biologics manufacturing to move the needle forward for development 

Breakout Session

Join your peers’ post-presentations to discuss over a series of questions applicable to your area of specialty

Small Molecule

Synopsis

  • What are the technological capabilities required to advance continuous-informed small molecule production?
  • What are some methods of proactive risk management to stabilize the shift to continuous?
  • How to accelerate adoption for all small molecule therapeutics?

Large Biologics

Synopsis

  • What are the technological capabilities required to advance continuous-informed biologics production?
  • What are some methods of proactive risk management to communicate internally?
  • How to accelerate adoption for more biologic therapeutics?

1:30pm Networking Lunch